NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
Pfizer
University of Pittsburgh
M.D. Anderson Cancer Center
Genta Incorporated
Pfizer
Vical